Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Blauvelt A, et al. Among authors: rosmarin d. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
The Boundaries of Critiquing a Colleague.
Rosenbaum KB, Rosmarin D. Rosenbaum KB, et al. Among authors: rosmarin d. J Am Acad Psychiatry Law. 2021 Dec;49(4):470-472. doi: 10.29158/JAAPL.210098-21. J Am Acad Psychiatry Law. 2021. PMID: 34903577 No abstract available.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
Toxic epidermal necrolysis.
Pereira FA, Mudgil AV, Rosmarin DM. Pereira FA, et al. J Am Acad Dermatol. 2007 Feb;56(2):181-200. doi: 10.1016/j.jaad.2006.04.048. J Am Acad Dermatol. 2007. PMID: 17224365 Review.
Images in clinical medicine. Inguinal hernia.
Rosmarin D, Tan CS. Rosmarin D, et al. N Engl J Med. 2006 Aug 10;355(6):601. doi: 10.1056/NEJMicm050827. N Engl J Med. 2006. PMID: 16899780 Free article. No abstract available.
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G. Kolbinger F, et al. Among authors: rosmarin d. Pharmacol Ther. 2022 Jan;229:107925. doi: 10.1016/j.pharmthera.2021.107925. Epub 2021 Jun 23. Pharmacol Ther. 2022. PMID: 34171337 Free article. Review.
176 results